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ABSTRACT 
 
SPROUTY2 DEFICIENCY IN MICE LEADS TO  
THE DEVELOPMENT OF ACHALASIA 
 
Sprouty 2 (Spry2), one of the four mammalian Spry family members, is a 
negative feedback regulator of many receptor tyrosine kinases (RTKs) signaling 
including Met. It fine-tunes RTKs signaling through multiple levels of regulations 
starting from RTK itself to several downstream molecules that are crucial for signal 
transduction.  To understand what role Spry2 might play during developmental 
processes, we created a Spry2 conventional knockout mouse in which Spry2 
expression is replaced by enhanced green fluorescent protein (EGFP) reporter. Spry2 
appears to be expressed in mouse embryo and in many adult tissues, and Spry2-
deficient mice have smaller body size and shorter lifespan. Pathologically, we 
observed that Spry2 deficiency results in impaired relaxation of the lower esophageal 
sphincter and mega-esophagus, a condition known as achalasia, which is likely due to 
malfunction of the innervated neurons where Spry2 is expressed. The Spry2-deficient 
mice may serve as a useful animal model for achalasia. Currently, we are 
investigating how loss of Spry2 leads to achalasia and whether the Met pathway plays 
a role in the development of this phenotype.  
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CHAPTER I 
 
INTRODUCTION 
 
Intracellular signaling is an intensely studied topic in current cell and 
molecular biology research.  The flow of information from the outside of the cell to 
the inside and the communication among the cellular components has revealed many 
fascinating discoveries, but much still remains unknown about the specifics of these 
communication pathways.  One group of cellular receptors that transfers signals 
across the cell membrane is the receptor tyrosine kinases (RTKs).  These 
transmembrane proteins play important roles in processes such as development and 
cancer progression; for example, RTKs have been shown to be integral in the 
functions of cell migration and proliferation, processes necessary in both a developing 
embryo and in cancer (Schlessinger, 2000). The pathways initiated by the receptors 
are regulated by a host of proteins designed to potentiate or inhibit the pathway and 
thereby allow close regulation of a variety of outcomes from a single receptor. 
One of these regulatory proteins was discovered to be a crucial inhibitor of 
tracheal branching during Drosophila embryonic development. Excessive branching 
of the trachea occurs when the gene for this protein is lost, so it was given the name 
Sprouty (Spry) (Hacohen et al., 1998). Spry presence among higher organisms has 
since been shown to be wide-spread, as homologous genes have been found in 
chickens (Chambers and Mason, 2000), frogs (Nutt et al., 2001), mice (Tefft et al., 
1999), and humans (Minowada et al., 1999). Tracheal branching in Drosophila is 
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normally regulated by fibroblast growth factor receptor (FGFR) signaling, so 
excessive branching in the absence of Spry gene provided the first evidence that Spry 
negatively regulates RTK signaling (Hacohen et al., 1998).  Negative feedback 
inhibition of a signaling pathway involves the transcription of a protein that limits the 
same pathway that led to its own transcription. Spry has been shown to be a negative 
feedback regulator of multiple RTKs including epidermal growth factor receptor 
(EGFR), FGFR, and hepatocyte growth factor receptor (HGFR, also known as Met), 
whose ligands can induce Spry gene expression (Hanafusa et al., 2002; Reich et al., 
1999; Ozaki et al., 2001; Hacohen et al., 1998; Lee et al., 2004). Spry fine-tunes 
RTKs signaling input in a timely manner, thereby influencing the signaling output as 
manifested by changes in cellular activities such as cell proliferation, migration, etc. 
(Kim and Bar-Sagi, 2004).  
The mitogen activated protein kinase (MAP kinase) pathway is a chain of 
protein-protein interactions by which the signal that was passed through the cell 
membrane is propagated, and terminates in regulation of gene transcription. 
Following the conformational change that occurs upon ligand binding, growth factor 
receptor-bound protein 2 (Grb2) is able to interact with the receptor as an adaptor 
protein, recruiting the guanine nucleotide exchange factor son-of-sevenless (Sos) to 
the cell membrane.  The small GPTase Ras can then interact with the Grb2-Sos 
complex, changing from the GDP to GTP conformation and thereby becoming 
activated.  Activated Ras binds and activates Raf, a serine-threonine protein kinase, 
which subsequently activates a series of kinases eventually leading to phosphorylation 
of a protein such as extracellular signal-regulated kinase (ERK) which translocates to 
the nucleus and regulates transcription factors for genes leading to cell growth and 
differentiation (Molina and Adjei, 2006). 
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Spry proteins can exert multiple levels of regulation on RTK signaling, 
starting from the receptor itself to several downstream signaling molecules (Kim and 
Bar-Sagi, 2004). One way Spry proteins inhibit Ras/MAP kinase pathway is by 
sequestering Grb2 so it cannot mediate the binding of Sos to the RTK, a step 
necessary for propagating the signal (Gross et al., 2001; Hanafusa et al., 2002). Sprys 
also bind to the protein kinase Raf through its conserved cysteine-rich domain, 
thereby inhibiting the activation of Raf and downstream ERK (Kim and Bar-Sagi, 
2004). Spry becomes inactivated when its tyrosine residues become dephosphorylated 
by Shp2 phosphatase (Hanafusa et al., 2004). This leads to disassociation of Spry 
from Grb2 and releases Spry-mediated signal inhibition (Hanafusa et al., 2004).  
Although Spry proteins seem to be general RTK inhibitors, the mode of Spry 
action on different RTKs does not appear to be exactly the same. For instance, FGF 
signaling is down-regulated by Spry2 while EGF signaling does not appear to be as 
greatly affected (Rubin et al., 2005). One method of down-regulating a signaling 
pathway is by marking components of the pathway for degradation by the 
proteasome. This marking is performed by the family of E3 ubiquitin ligases, a 
prominent member of which is c-Cbl. Spry proteins have also been found to increase 
MAP kinase signaling induced by EGF and this increase is likely due to the ability of 
Spry to sequester c-Cbl (Egan et al., 2002). Following phosphorylation, Spry can 
interact with the Src-homology 2-like domain of c-Cbl and block c-Cbl’s binding to 
EGFR, thus preventing EGFR ubiquitination and degradation (Egan et al., 2002; Fong 
et al., 2003). This is not the case in FGF-induced signal transduction as Spry shows 
no protection against FGFR ubiquitination (Fong et al., 2003). It has been suggested 
that the difference between FGF and EGF signaling is most likely due to the ability of 
FGFR but not EGFR to phosphorylate certain Spry carboxy-terminal tyrosine residues 
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necessary for full inhibitory function (Rubin et al., 2005). This selective 
phosphorylation may be a key to the extent Spry plays in regulating RTK signaling 
originating from different receptors. The ability for receptors to target specific 
tyrosines on the Spry proteins allows a single Spry protein enough versatility to 
display a variety of responses, depending on which receptor initiates its 
phosphorylation. 
There are four members in the mammalian Spry family. Two conserved 
regions among Spry protein family members account for their functions: a carboxy-
terminal cysteine rich domain is responsible for translocation of Spry from its pre-
stimulated location in the cytosol to the post-stimulated location at the plasma 
membrane (Lo et al., 2004; Lim et al., 2002). Phosphorylation of an amino-terminal 
conserved tyrosine upon growth factor stimulation is crucial for Sprys to inhibit RTK-
Ras-MAP kinase signaling cascade (Hanafusa et al., 2002; Gross et al., 2001; Kim 
and Bar-Sagi, 2004).  
One method of determining the role of a gene is to overexpress it in vitro or in 
vivo. Abnormalities that arise in the over-expression tissue often provide an indication 
of the gene’s function. Chick Spry over-expression results in stunting of chick limb 
outgrowth by preventing proper bone formation (Minowada et al., 1999). Over-
expression of the mouse Spry2 protein in vitro results in decreased cell proliferation, 
migration, and invasion, as well as accumulation of cells at cell cycle phase G2/M 
(Lee et al., 2004). Endogenous levels of Spry1 and Spry2 proteins negatively regulate 
proliferation, differentiation, and anchorage-independent cell growth (Gross et al., 
2001), while promoting cell adhesion and spreading (Lee et al., 2004).  
One common means to identify the effect a gene has on development is the 
creation of a knockout mouse in which the gene of interest is removed and the 
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development of the mouse is followed.  Anomalies from standard development 
indicate the deleted gene may be influential in the development of the system that 
produced the difference observed. Spry1 knockout mice suffer from a ureteric bud 
defect that is attributed to loss of Spry1 in the Wolffian duct during embryogenesis, 
leading to multiple ureters and epithelial cysts on the kidneys (Basson et al., 2005). 
Spry2 knockout mice have also been created and are described in the discussion 
section. There have been no reports of Spry3 knockout mice. Spry4 knockout mice 
exhibit lower body weights than wild type mice, exhibit polysyndactyly, and have 
mandible defects (Taniguchi et al., 2007). 
Spry2 has been shown to be induced in leiomyosarcoma cells by hepatocyte 
growth factor (HGF) and acts as a negative feedback inhibitor of the Met pathway 
(Lee et al., 2004) which is involved in both embryogenesis and tumorgenesis 
(Birchmeier et al., 2003). This paper also showed that overexpression of Spry2 leads 
to inhibition of HGF-induced AKT and ERK signaling, as AKT phosphorylation was 
completely abolished and the duration of ERK phosphorylation was reduced. Cell 
proliferation and invasion were also inhibited when Spry2 was overexpressed (Lee et 
al., 2004). These attributes are characteristic of tumor suppressor genes, and Lee et al. 
were the first to suggest that Spry2 is a tumor suppressor gene. 
Previously published data and results within our lab led us to ask questions 
related to the role Spr2 plays in the mouse. What happens in vivo when regulation of 
the RTKs by Spry2 is lost? Will mice without Spry2 develop tumors more quickly 
than mice with normal Spry2 levels? What happens to mouse development when 
Spry2 is lost? 
We wanted to determine what role Spry2 might play during normal 
development; we generated a Spry2 knockout mouse in which Spry2 alleles are 
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replaced by an enhanced green fluorescent protein (EGFP) reporter using a 
conventional gene targeting technology. In this mouse model we see evidence for 
Spry2 expression in several embryonic and adult tissues as indicated by EGFP 
fluorescence. Pathologically, Spry2-deficient mice display an enlarged esophagus and 
much smaller body size as well as a shorter lifespan than wild type and heterozygous 
littermates, likely due to developmental/functional defect in the lower esophageal 
sphincter which fails in relaxation or is hypercontractile, a condition known as 
achalasia. 
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CHAPTER II 
 
RESULTS 
 
To investigate the role of Spry2 during mouse development, we created Spry2-
deficient mice using conventional gene knockout techniques. The entire coding region 
of Spry2 was replaced with an EGFP/PGK-Neo cassette, leaving EGFP expression 
under the control of endogenous Spry2 promoter (Figure 1A). The expected 
homologous recombination of Spry2 alleles was confirmed by Southern blot analysis 
and PCR genotyping using genomic DNAs derived from Spry2 wild type, 
heterozygous and homozygous mice (Figure 1B).  
We first examined the expression of Spry2 in various tissues including brain, 
lung, and kidney of wild type, heterozygous, and Spry2 homozygous mice by reverse 
transcriptase PCR (RT-PCR). Spry2 displays highest expression in the brain, and 
moderate expression in the lung and kidney of Spry2 wild type mice (Figure 2A). No 
Spry2 expression was detected in the tissues derived from Spry2-/- mice, indicating a 
complete Spry2 knock-out (Figure 2A). This was also confirmed by the detection of 
EGFP in tissues derived from Spry2+/- and Spry2-/- mice but not Spry2+/+ mice either 
by RT-PCR (Figure 2A) or western blot analysis (Figure 2B). DNA, RNA, and 
protein results all indicate accurate homologous recombination in the Spry2 alleles. 
Mouse embryo and adult tissues were also examined under a fluorescence 
microscope to determine the expression sites of Spry2, as seen by EGFP reporter 
fluorescence in the Spry2-deficient animal. Spry2-/- embryos show strong fluorescence 
in the developing ear and limbs, whereas Spry2+/+ embryos show only background 
fluorescence (Figure 3A). Strong EGFP fluorescence was also observed from Spry2-/- 
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adult brain, while moderate fluorescence was observed from lung, heart, and kidney 
of three-month old Spry2-/- mice (Figure 3B). These data are consistent with the 
results obtained from RT-PCR and western blot analysis (Figure 2).  
Spry2 wild type, heterozygous and homozygous mice were born in the 
expected Mendelian ratio, indicating no embryonic lethality due to Spry2 deficiency. 
There is no obvious difference in littermate sizes at birth, but later on Spry2-/- mice 
appear to be smaller than their wild type and heterozygous littermates, indicating 
growth retardation is likely a result of a postnatal defect (Figure 4A). The average 
body weight of the Spry2-/- mice was only two-thirds of the Spry2+/+ and Spry2+/- 
mice (Figure 4A). Upon gross examination, the most obvious difference that we 
observed was the appearance of the esophagus (Figure 4B). While other organs 
appear proportional to the body size, Spry2-/- mice have a megaesophagus with an 
average diameter more than twice as large as wild type or heterozygous littermates 
(Figure 4B). The increased diameter extends down to, but does not appear to include, 
the lower esophageal sphincter (LES). Longitudinal sections through the LES and 
adjoining esophagus reveal an enlarged lumen and dilated wall, while the LES 
appears to be in a contractile state (Figure 4C), mimicking a pathological condition 
known as achalasia in humans. This phenotype is likely due to a blockage between the 
esophagus and stomach resulted from either nonrelaxation or hypercontraction of the 
LES. Food and water cannot pass properly through the LES into the stomach due to 
the defect, and as a result the Spry2-deficient mice are malnourished, appear skinny, 
and are short-living. There is an inverse correlation between body weight and 
esophagus size (Figure 4A and 4B).  
When examining the location of Spry2 expression in the Spry2-/- esophagi 
under a fluorescent microscope, we observed a bright EGFP fluorescence, indicating 
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of Spry2 expression, along the longitudinal nervous tissues of the esophagus running 
to the LES region (Figure 4D). This suggests that a potential defect in the neuronal 
tissues innervating the LES may result in achalasia in the Spry2-/- mice.  
To determine if the esophageal phenotype is due to an unregulated Met 
signaling in neuronal tissues, we then asked if eliminating Met activity will rescue or 
alleviate the Spry2-deficient phenotype. Selective knockout of genes in specific 
tissues can be obtained using the cre-lox conditional knockout system (Sternberg and 
Hamilton, 1981; Nagy, 2000) in which regions of DNA flanked by LoxP sites can be 
deleted only in tissues expressing the cre enzyme. Only one copy of cre recombinase 
(cretg/-) is necessary and sufficient to excise any regions flanked by LoxP sites. Since 
complete knockout of Met is embryonically lethal (Bladt et al., 1995), we 
conditionally knocked out the Met allele in neuronal tissues by crossing MetLoxP/LoxP 
mice (Borowiak et al., 2004) to nestin-cretg/- mice in which cre recombinase is 
specifically expressed in the neuronal tissues under the control of nestin gene 
promoter (Burns et al., 2007). Using the mating scheme outlined in Figure 5, we 
aimed to obtain animals with MetLoxP/LoxP; nestin-cretg/-; Spry2-/- genotype to achieve 
Spry2-deficiency in conjunction with Met alleles specifically knocked out in neuronal 
tissues. However, no animals of this genotype have been observed thus far. 
To determine how loss of Spry2 affects RTK signal transduction in vitro, we 
established mouse embryonic fibroblast (MEF) cell lines from Spry2 wild type, 
heterozygous, and homozygous embryos. A more robust ERK phosphorylation was 
observed in Spry2-/- MEF cells upon EGF stimulation, compared to that in the 
Spry2+/+ and Spry2+/- cells (Figure 6), indicating that releasing negative regulation 
from Spry2 may enhance the RTK signaling. 
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CHAPTER III 
 
DISCUSSION 
 
While most studies have focused on in vitro analysis of the pathways Spry2 
affects (Lee et al., 2004; Chambers and Mason, 2000; Hanafusa et al., 2002), we 
aimed to examine the role of Spry2 in vivo and to determine how loss of Spry2 may 
affect mouse development. In this study we created and characterized a Spry2 
knockout mouse in which the Spry2 gene is replaced by an EGFP reporter. We 
observed that loss of Spry2 results in a postnatal defect in the esophagus as 
manifested by a severely dilated and enlarged esophagus and nonrelaxation or 
hypercontraction of the lower esophageal sphincter (LES) (Figure 4), a condition 
known as achalasia in humans (Richter, 2010). Spry2 appears to be expressed in the 
enteric nerve tissues of the esophagus, especially around the LES, as evidenced by the 
EGFP fluorescence (Figure 4D). Identification of endogenous Spry2 presence in the 
esophageal neuronal tissue suggests a possible role for Spry2 in controlling sphincter 
function. The LES appears to be an important location of Spry2 activity, which is 
consistent with published data showing LES contraction in Spry2 null mice to be five 
times as strong as wild type mice (Taketomi et al., 2005).  
Spry2 is the most closely studied isoform among all Spry family members for 
its role in cancer (Lo et al., 2004; McKie et al., 2005; Fong et al., 2006). Even though 
Spry2 is highly expressed in the brain and moderate in tissues such as lung and kidney 
(Figure 3), we observed no spontaneous tumor formation in Spry2-deficient mice, 
suggesting that loss of Spry2 alone is not sufficient for tumorigenesis. Other labs 
publishing Spry2 knockout mice phenotypes have not described tumor formation as a 
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result of Spry2 loss either. It is also possible that other Spry family members may be 
compensating somewhat for Spry2 loss, preventing or suppressing tumor formation 
while other phenotypes of Spry2 deficiency are still visible. It remains to be seen if 
the diffenential phosphorylation of Spry2 residues in response to various growth 
factors plays a role in tumor formation. 
Two other research groups have reported phenotypes lacking Spry2 in mice: 
one described a severe hearing impairment (Shim et al., 2005), and the other showed 
an esophageal phenotype similar to the one we observed (Taketomi et al., 2005). The 
hearing impairment defect in Spry2-deficient mice has been attributed to excessive 
FGF signaling which leads to the development of an extra pillar cell in the inner ear 
(Shim et al., 2005). Glial cell derived neurotrophic factor (GDNF) signaling was 
reported to be responsible for developing Spry2-deficient esophageal phenotype 
(Taketomi et al., 2005). In the latter case, the authors conclude that loss of Spry2 
results in enteric nerve hyperplasia, based on counting immunostained neurons from 
mouse esophagus and colon (Taketomi et al., 2005). Injection of neutralizing antibody 
against GDNF or an antagonist of Ret (the receptor tysosine kinase for the GDNF 
ligand) into neonatal Spry2-/- mice alleviated some of the esophageal phenotype 
(Taketomi et al., 2005), although the animals were followed for only a short time 
window that may not have taken into account the incomplete penetrance we see in our 
Spry2-deficient animals. Ret germline inactivating mutations are the cause of about 
half the cases of a human condition known as Hirschsprung’s disease. This condition 
is manifested by megacolon due to a defect in the enteric innervation known as 
intestinal aganglionosis (Arighi et al., 2005). It seems that the esophagus is spared 
from defect due to Ret deficiency, as knocking out Ret in mice causes intestinal 
aganglionosis but only partially affecting enteric innervation in the esophagus 
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(Durbec et al., 1996). Yet, another report showed that neural cells in the esophagus 
are Ret-dependent (Yan et al., 2004). There seems to be no direct evidence showing 
that the Spry2-deficient esophageal phenotype is caused by GDNF-Ret pathway. A 
direct approach to test this hypothesis would be to cross Spry2 knockout mice with 
Ret-deficient mice and determine if loss of Ret activity rescues achalasia resulted 
from Spry2 deficiency.  
Interestingly, it has also been reported that GDNF can induce Met 
phosphorylation in Ret-deficient cells (Popsueva et al., 2003), suggesting that Met 
may mediate Ret-independent GDNF signaling in certain cell contexts. This option of 
GDNF signaling through the Met receptor opens the possibility of crosstalk between 
the HGF-Met and GDNF-Ret pathways. If this is the case in Spry2-deficient mice, the 
results of the anti-GDNF experiment in the paper by Taketomi et al. may have been 
dependent on Met signaling also.  
The Met gene codes for an RTK that has been shown to play an important role 
both in embryonic development and in cancer metastasis. Met has a key function in 
placenta formation, liver development, myogenic precursor cell spread, and 
integration of the nervous system (for reviews, see Birchmeier et al., 2003; Trusolino 
et al., 2010). HGF binds the Met receptor and initiates several signaling pathways that 
lead to proliferation, migration, invasion, or other cellular outcomes (Birchmeier et 
al., 2003).  
Since Spry2 is a negative feedback regulator of HGF-Met signaling pathway, 
we asked if Met plays a role in the development of achalasia phenotype in Spry2-
deficient mice. Met knock-in (Metki) mouse lines in which a cassette derived from Met 
cDNA was introduced into the Met locus have been produced (Graveel et al., 2005). 
The mice with this insertion but lacking Met activation mutations developed severe 
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megaesophagus, however various constitutive activating mutations in the cassette 
rescued the phenotype (unpublished results). Although it could be predicted that loss 
of Spry2 in the presence of hyperphosphorylated active Met would enhance the 
esophageal phenotype, crossing our Spry2 line to a line with one of these activating 
mutations did not significantly alter the esophageal diameter or the lifespan of the 
Spry2-deficient mice (unpublished data). Crossing Spry2-deficient mice to the Metki 
line with no mutations should answer the question if Metki/ki; Spry2-/- mice have an 
even larger esophagus or if they are even viable at all. 
HGF is a chemoattractant for motor neurons during development and guides 
neuron outgrowth (Maina and Klein, 1999).  HGF also patterns the axonal outgrowth, 
and HGF mutant mice have been found to have defective motor axon growth (Miana 
et al., 2001). In addition, Met has been reported to play an important role in axonal 
development, with Met mutant mice developing shorter nerves that have fewer 
branching points than wild type mice (Miana et al., 1997). Anti-HGF antibodies can 
stunt the differentiation of sympathetic neurons, and survival and growth of these 
neurons are significantly enhanced with HGF (Miana et al., 1998).  
Two major pieces of evidence pointed us toward examining the role of Spry2 
in mouse development: 1) HGF has been shown to upregulate Spry2 expression (Lee 
et al., 2004), and 2) the HGF-Met pathway is crucial in neuronal development (Miana 
et al., 1997; Miana et al., 1998; Miana et al., 2001). Given the Met signaling 
importance in neuronal development and its negative regulation by Spry2, we 
speculated that Met might play a role in the development of achalasia in Spry2-/- mice. 
Therefore, we hypothesized that Met signaling is responsible for the migration of 
neural crest cells into the esophagus. Absence of Spry2 leads to enhanced Met 
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signaling in the neural crest cells, likely leading to hyperganglionosis in the 
esophagus.  
To test our hypothesis, we asked if eliminating Met activity rescues the 
esophageal phenotype developed by the Spry2-deficient mice. If Met is the driver of 
this phenotype, eliminating Met should restore the normal esophageal phenotype. 
Since complete knockout of either Met or HGF results in embryonic lethality (Bladt et 
al., 1995; Schmidt et al., 1995; Uehara et al., 1995), we took an approach to 
conditionally knockout Met in the neuronal tissues by crossing Met-flox mice 
(Borowiak et al., 2004) with nestin-cre transgenic mice in the absence of Spry2 (see 
Figure 5 for breeding scheme). However, we have not yet obtained any mice 
exhibiting either a MetLoxP/+;Nestin- cretg/-; Spry2-/- or MetLoxP/LoxP;Nestin- cretg/-; 
Spry2-/- genotype. Albumin-cre mice express cre recombinase in the liver (Postic et 
al., 1999), and crossing these mice with MetLoxP/LoxP, Spry2-/- mice can produce a 
MetLoxP/LoxP; albumin-cretg/-; Spry2-/- mouse, ruling out a possible background effect 
due to the cre mouse strain. MetLoxP/LoxP;Nestin- cretg/-; Spry2+/+ mice are also viable, 
indicating that the loss of Met in the neuronal tissue alone is not lethal. Two 
possibilities may account for the lack of the two mouse genotypes: 1) there have not 
been enough pups born to see the genotypes we are seeking, or 2) those two 
genotypes are embryonically lethal. We are currently investigating these possibilities.  
Taken together, we show that Spry2 is expressed in the enteric nerve 
innervations of the esophagus and its deficiency results in the development of 
esophageal achalasia. We are aiming to gain further insight into how this condition is 
developed in the absence of Spry2 and whether Met plays a role in its onset. The 
Spry2 knockout mouse can be a useful model for understanding the underlying 
mechanism of achalasia and for developing therapies for this condition.  
15 
 
CHAPTER IV 
 
MATERIALS AND METHODS 
 
 Generation of Spry2 Knockout Mouse  
To construct a Spry2 targeting vector as shown in (Figure 1A), a 2-kb genomic 
fragment (including partial intron 1 and partial exon 2) and a 4.6-kb genomic 
fragment downstream of exon 2 were inserted into the pPNT vector (Tybulewicz et 
al., 1991) ahead of and behind an EGFP-PGK-NEO cassette, respectively. In the 
resulted vector, the EGFP reporter uses the ATG codon from Spry2 gene as its 
starting codon. Once homologous recombination takes place, the entire coding region 
of Spry2 is replaced by the EGFP-PGK-NEO cassette, and the EGFP reporter is under 
the control of Spry2 promoter for its expression. To generate ES cells carrying the 
Spry2+/- genotype, ES cells were electroporated with a linearized targeting vector and 
selected with neomycin. Two established Spry2+/- ES clones were used to generate 
Spry2 knockout mice. Successive homologous recombination was confirmed by 
Western Blot analysis and PCR genotyping as detailed below.  
 
Southern Blot Analysis 
Mouse tails were clipped at weaning and were submitted to automatic DNA 
extraction by an AutoGenPrep 960 machine (AutoGen). DNA was then digested with 
restriction enzymes NdeI and HindIII, separated via electrophoresis, and transferred to 
a Hybond XL membrane. The Sy2-5’ probe (Figure 1A) was radiolabeled with 32P, 
hybridized with the membrane, and detected on a Kodak x-ray film. 
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PCR Genotyping 
For PCR genotyping of Spry2, three primers (P1, P2, and P3) were used in a 
mixed reaction to distinguish wild type and mutant alleles (Figure 1A). The forward 
primer P1 (5’-GACTTGACCGATACGTTGTAGG-3’) is common to both wild type 
and mutant alleles. The reverse primer P2 (5’-ATCAGGTCTTGGCAGTGTGTTC-
3’) is specific for wild type allele, while P3 (5’-ATGAACTTCAGGTCAGCTTGC-
3’) is specific for mutant allele. PCR amplification used an annealing temperature of 
58°C and an elongation period of two minutes for 30 cycles. Genotypes were 
determined by separating the PCR products on a 1.2 % agarose gel containing 
ethidium bromide, followed by visualization under UV light.  
 
Other Mouse Strains 
Nestin-cre animals were purchased from Jackson Laboratories (www.jax.org). 
Met-flox mice were obtained from Dr. Carmen Birchmeier (Max Delbrück Center for 
Molecular Medicine, Germany).  
 
RT-PCR 
Brain, lung, and kidney tissues were harvested and homogenized in 4 mL of 
TRIzol reagent (Sigma-Aldrich). RNA extraction proceeded according to the TRIzol 
protocol. A One-Step RT-PCR Kit (Invitrogen) was employed according to the 
manufacturer’s recommendations, using primers as follows: 5’-
CAGATGTGTTCTAAGCCTGCTG-3’ and 5’-GAGCAACAATCCCTATTACTGC-
3’ for Spry2; 5'-AAGGACGACGGCAACTACAAG-3' and 5'-
CGGATCCGCTCGAGCGCCTTAAGATACATTGATGAG-3' for EGFP; 5'-
TCCAGTATGACTCCACTCACG-3' and 5'-ACAACCTGGTCCTCAGTGTAG-3' 
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for GAPDH. PCR products amplified using an annealing temperature of 55 °C and an 
elongation time of one minute (30 cycles) were run on a 1 % agarose gel containing 
ethidium bromide and visualized under UV light.  
 
Tissue Culture 
Mouse Embryonic Fibroblasts (MEFs) were established from day-14 
individual embryos and cultured in DMEM (Invitrogen) supplemented with 10% Fetal 
Bovine Serum (HyClone) and 1% Penicillin/Streptomycin. Following establishment, 
the MEF cells genotypes were determined by PCR.  
 
Western Blot Analysis 
Mice were sacrificed and the brain, lung, and kidney of each mouse was 
homogenized separately in RIPA buffer [50 mM Tris-HCl, pH 7.4, 1 % NP-40, 
0.25 % Na-deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 µg/mL 
Aprotinin, 1 µg/mL leupeptin, 1 µg/mL pepstatin, 1 mM Na3VO4, 1 mM NaF, 
Complete Protease Inhibitor Tablet (Roche Applied Science)]. Subsequently, samples 
were frozen in liquid nitrogen to rupture the cells, thawed at 4 °C, and centrifuged at 
13,500 rpm for fifteen minutes.  
To collect tissue culture lysates, cells were rinsed with phosphate buffered 
saline (PBS) and RIPA was added. Following 15 minute incubation at 4°C, cell debris 
was removed by centrifugation at 13,500 rpm for 15 min. Protein lysates were 
quantified using the DC Protein Assay (Bio-Rad) according to manufacturer’s 
specifications, and diluted to equal concentrations in 2X Laemmli Sample Buffer 
(Sigma). Proteins were denatured by boiling for five minutes and then loaded into a 
10 % Tris-Glycine PAGE gel (Invitrogen) in equal concentrations. The gel was run at 
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125 volts for approximately two hours, and transferred to a PVDF membrane 
(Invitrogen) via electrophoresis at 25 volts for two hours. The membrane was blocked 
with 5 % dry milk for one hour, and probed overnight at 4 °C with the primary 
antibody. Membranes were washed with Tris Buffered Saline with Tween (TBST), 
probed with the appropriate anti-rabbit or anti-mouse secondary antibody (Amersham 
Biosciences RPN2108) for one hour at room temperature, and then washed again. 
Blots were developed on X-ray film using an Amersham Biosciences ECL kit 
(RPN2108). The primary antibodies used were: GFP (AbCam ab290, 1:1000), 
phospho-ERK (Cell Signaling #9101S, 1:1000), and β-actin AC-17 (Sigma-Aldrich 
A1978, 1:10,000).  
 
Paraffin Embedded Tissue Slide Preparation 
Tissues were fixed overnight in formalin, embedded in paraffin wax, cut in 5 
µm sections, and stained with hematoxylin and eosin.  
 
Fluorescence Microscopy 
Ectopic Spry2 expression was investigated by examining EGFP fluorescence 
in embryo and adult tissues. Organs extracted from sacrificed mice or whole embryos 
(day-15 old) were directly viewed under UV illumination using a Leica MZ FLIII 
fluorescence stereomicroscope for EGFP fluorescence. The esophagus was opened 
longitudinally and splayed for examination under a Zeiss LSM510 META Confocal 
Microscope. 
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Figure 1. Targeted disruption of mouse Spry2 wild type alleles. (A) Diagram of the 
gene targeting vector for the Spry2 knockout mouse, and the genomic structures of the 
wild type (WT) and mutant alleles, respectively. After homologous recombination, 
the entire coding region within exon 2 (E2) was deleted and replaced with a cassette 
containing EGFP and PKG-NEO. The EGFP sequence was linked to the leftover short 
fragment of E2 and its expression is under the control of Spry2 gene promoter. The 
indicated restriction enzyme sites are: B, BamH I; E, EcoR I; H, Hind III; N, Nde I. 
(B). Determining Spry2 WT and mutant alleles by Southern Blot analysis and PCR 
genotyping. The mouse genomic DNA was digested by Nde I and Hind III, and the 
blot was hybridized with 32P-labeled Sy2-5’ probe. A 9.2 kb WT band and an 8.2 kb 
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mutant band were detected accordingly. PCR genotyping was performed using primer 
pair P1-P2 for WT allele and P1-P3 for mutant allele. 
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Figure 2. EGFP replaces Spry2 expression in Spry2 heterozygous and homozygous 
mice. (A) Reverse Transcriptase-PCR detection of Spry2 and EGFP in mouse tissues. 
Total RNA was prepared from brain, lung, and kidney derived from Spry2+/+, Spry2+/-, 
and Spry2-/- mice. RT-PCR was performed using primer pairs specifically for mouse 
Spry2 and EGFP. GAPDH was also amplified as an internal control. (B) Detection of 
EGFP protein in Spry2 heterozygous and homozygous mouse tissues. Whole protein 
extract was prepared from the indicated mouse tissues, subjected to Western Blot 
analysis, and probed with anti-GFP and anti-β-actin antibodies. 
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Figure 3. Visualization of Spry2 expression in embryo and adult tissues of Spry2-
deficient mice revealed by EGFP fluorescence. (A) Spry2+/+ and Spry2-/- embryos at 
embryonic day 15. Green fluorescence represents EGFP expression. (B) Adult brains, 
lungs, kidneys and hearts derived from three months old Spry2+/+ and Spry2-/- mice 
were visualized under a Leica FLUO III microscope.  
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Figure 4. Spry2 deficiency results in growth retardation and mega-esophagus in 
Spry2-/-mice. (A) Upper: Appearances of three months old Spry2+/+, Spry2+/- and 
Spry2-/- mice. Spry2-/- mice display a much smaller body size than the Spry2+/+ and 
Spry2+/- littermates of the same age. Lower: Average mouse mass as measured at the 
time of necropsy. (B) Upper: Gross anatomy of esophagus and stomach derived from 
Spry2+/+, Spry2+/- and Spry2-/- mice, respectively. The Spry2-/- mouse esophagus is 
twice as large in diameter as that of wild type or heterozygous littermates. The bottom 
part of the mutant esophagus at the lower esophageal sphincter (LES) region does not 
appear enlarged. Lower: Average esophagus diameter at the time of necropsy. n.s. = 
no significant difference, *** = p < 0.001 by Student’s T-test, Spry2+/+ n=26, Spry2+/- 
n=58, Spry2-/- n=96, error bars = standard deviation (C) Hematoxylin and eosin 
staining of the Spry2-/- mutant esophagus revealed enlarged lumen space with marked 
hyperkeratosis. The esophagus-stomach junction does not appear to be enlarged. (D) 
Left panel shows gross visualization of EGFP fluorescence in the esophagus derived 
from 3 months old Spry2+/+ and Spry2-/- mice. Right panel shows high-power confocal 
image of EGFP fluorescence revealing the neuronal network in the mutant esophagus. 
Arrowhead indicates the location of LES; arrows indicate nerve tissues with strong 
fluorescence across the mutant esophagus and especially around the LES region. 
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Figure 5. Mating scheme for conditional knockout of Met in the neuronal tissues of 
Spry2-deficient mice. Spry2+/- mice are crossed to MetloxP/loxP and Nestin-cretg/- mice 
to generate MetloxP/loxP;Nestin-cretg/-;Spry2-/- mice for determining the role of Met in 
the development of the Spry2-/- esophageal phenotype. Values in parentheses are the 
expected percentages of offspring with the indicated genotype. 
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Figure 6. Loss of Spry2 causes ERK/MAPK hyperactivation in response to growth 
factor stimulation in Spry2-/- MEF cells. MEF cell lines were established from 
prenatal Spry2+/+, Spry2+/- and Spry2-/- mouse embryos (day 15). Cells were plated in 
6 well dishes, serum starved overnight, and then stimulated with EGF (50 ng/mL) for 
the indicated times. Whole cell lysates were prepared and subjected to Western Blot 
analyses. The blots were probed with phospho-p44/42 MAPK (p-ERK), GFP, and β-
actin antibodies sequentially. 
 
